Seroatlas · Human Serome Atlas

PLAAT2

Phospholipase A and acyltransferase 2

Also known as: FLJ20556, HRASLS2, PLAAT-2, PLAT2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NWW9
Gene: PLAAT2
Ensembl: ENSG00000133328
Chromosome: 11
Canonical length: 162 aa
Protein class: Enzymes, Metabolic proteins, Predicted membrane proteins, RAS pathway related proteins
Subcellular location: Mitochondria

OverviewNCBI Gene

The protein encoded by this gene has both phospholipase and acyltransferase activities and acts as a tumor suppressor. The encoded protein can hydrolyze dipalmitoylated phosphatidylcholine (PC) to palmitic acid and lyso-PC. In addition, this protein can catalyze the N-acylation of phosphatidylethanolamine and can catalyze the O-acylation of lyso-PC to form PC. [provided by RefSeq, Jul 2016]

Canonical amino-acid sequenceUniProt

162 residues, UniProt reviewed canonical sequence.

>Q9NWW9|PLAAT2
     1  MALARPRPRL GDLIEISRFG YAHWAIYVGD GYVVHLAPAS EIAGAGAASV LSALTNKAIV
    61  KKELLSVVAG GDNYRVNNKH DDRYTPLPSN KIVKRAEELV GQELPYSLTS DNCEHFVNHL
   121  RYGVSRSDQV TGAVTTVGVA AGLLAAASLV GILLARSKRE RQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PLAAT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 64 nTPM

Expression across tissuesHPA

Tissue

duodenum: 64 nTPM
small intestine: 40 nTPM
rectum: 13 nTPM
stomach: 12 nTPM
colon: 10 nTPM
breast: 8.5 nTPM

Single-cell type

foveolar cells: 124 nCPM
epididymal efferent duct ciliated cells: 91 nCPM
enterocytes: 79 nCPM
colonocytes: 75 nCPM
respiratory ciliated cells: 64 nCPM
endometrial ciliated cells: 54 nCPM

Immune cell

memory B-cell: 17 nTPM
naive B-cell: 8.3 nTPM
total PBMC: 3.9 nTPM
NK-cell: 1.7 nTPM
memory CD8 T-cell: 1 nTPM
gdT-cell: 0.9 nTPM

Brain region

white matter: 1.6 nTPM
cerebral cortex: 0.8 nTPM
medulla oblongata: 0.8 nTPM
basal ganglia: 0.7 nTPM
amygdala: 0.6 nTPM
pons: 0.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.83
gnomAD pLI: 0
DepMap mean gene effect: -0.05
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PLAAT2 as an antibody target. Whether an autoantibody or antibody against PLAAT2 could matter depends on whether native PLAAT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PLAAT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PLAAT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...